Orbitrap HRMS‐Based Comprehensive Metabolite Characterization of Duvelisib in Cross‐Species Hepatocytes
Duvelisib (DVB), a selective PI3K‐δ/γ inhibitor approved for chronic lymphocytic leukemia, requires detailed metabolic characterization to support early drug development and selection of appropriate toxicology species. Because drug metabolism varies across species, an integrated system such as primary hepatocytes conta...